Clinical Trials Directory

Trials / Completed

CompletedNCT02069821

Pharmacokinetic Interactions Between Amlodipine Besylate/Valsartan and Atorvastatin in Healthy Male Subjects

An Open-label, Multiple-dosing, Two-arms, One-sequence Study to Evaluate the Safety and Pharmacokinetics After Co-administration of Exforge® (Amlodipine Besylate/Valsartan) and Lipitor® (Atorvastatin Ca) in Healthy Male Volunteers

Status
Completed
Phase
Phase 1
Study type
Interventional
Enrollment
56 (actual)
Sponsor
HK inno.N Corporation · Industry
Sex
Male
Age
20 Years – 45 Years
Healthy volunteers
Accepted

Summary

The purpose of the study is to assess the pharmacokinetic interactions between amlodipine besylate/valsartan and atorvastatin single or co-administered in healthy volunteers.

Conditions

Interventions

TypeNameDescription
DRUGcombination administrationcombination administration : amlodipine/valsartan 10/160mg and atorvastatin 40mg, qd, 10days(oral)

Timeline

Start date
2014-03-01
Primary completion
2014-03-01
Completion
2014-07-01
First posted
2014-02-24
Last updated
2017-09-12

Locations

1 site across 1 country: South Korea

Source: ClinicalTrials.gov record NCT02069821. Inclusion in this directory is not an endorsement.

Pharmacokinetic Interactions Between Amlodipine Besylate/Valsartan and Atorvastatin in Healthy Male Subjects (NCT02069821) · Clinical Trials Directory